Recent Updates
Recently added Catalysts

Test formulation administered with water

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Dec 11, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment19
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01677039Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release FormulationPHASE1 COMPLETED 19Sep 1, 2012Dec 1, 2012Dec 11, 20121 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Maximum observed oxycodone concentration in plasma (Cmax)
hours after dosing
Area under the oxycodone concentration versus time curve (AUC)
hours after dosing
Secondary Endpoints
Time-to-peak concentration (Tmax)
hours after dosing
half-life of drug
hours after dosing
Vital signs and adverse events
hours after dosing
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Treatment AACTIVE_COMPARATOR -
Treatment BEXPERIMENTAL -
Treatment CEXPERIMENTAL -
Interventions
NameTypeDescription
Test formulation administered with waterDRUGsingle dose of 20 mg of test formulation with 240 mL of water
Test formulation administered with 20% ethanolDRUGsingle dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
Test formulation administered with 40% ethanolDRUGsingle dose of 20 mg of test formulation with 240 mL of 40% ethanol
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * healthy volunteers * history of moderate alcohol consumption * total body weight exceeding 64 kg Exclusion Criteria: * history of clinically significant disease * history of sleep apnea * any condition affecting drug absorption * pregnant or nursing female subjects * history...

Countries:United States
Unlock Eligibility Criteria